Scientific Meeting Highlights from SITC

ASH Annual Meeting 2024 (Dec. 7–9)

By Thomas Martin posted 2 days ago
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ASH Annual Meeting 2024. Below is a recap of highlighted research presented from Dec. 7 –9, 2024. 2024 Scientific Highlights Safety and efficacy of Meta10-19, an IL-10 expressing CD19 CAR T-cell therapy for relapsed or refractory B-cell malignancies 92. IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies Yongxian Hu (Zhejiang University School of Medicine, Zhejiang University, ...
0 comments

SITC 2024 Science Coverage – Nov. 10

By Keegan Mager posted 11-11-2024
Artificial intelligence- and machine learning-based approaches to identify biomarkers of patient response to immunotherapy for non-small cell lung cancer 77. Predicting the tumor microenvironment molecular composition to assess immunotherapy efficacy in non-small cell lung cancer from digital histopathology images Alex Chen (National Cancer Institute, Bethesda, MD, USA) described a novel artificial intelligence- (AI-) based approach to characterize the composition of the tumor microenvironment (TME) using histopathology images of samples from patients with non-small cell lung cancer (NSCLC) and how to use this characterization as a predictive ...
0 comments

SITC 2024 Science Coverage – Nov. 9

By Keegan Mager posted 11-10-2024
Safety and clinical activity of invikafusp alfa, a selective T cell activator, against antigen-rich solid tumors 1470. START001: A Phase 1/2 study of Invikafusp alfa (STAR0602), a first-in-class TCR β chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1 James Gulley (National Cancer Institute, Bethesda, MD, USA) presented results from the STARt-001 trial, phase 1/2 study investigating invikafusp alfa, a dual T cell agonist for the treatment of anti-PD(L)1-resistant, antigen-rich solid tumors. Invikafusp alfa is a selective T cell activator consisting of a selective Vβ T ...
0 comments

SITC 2024 Science Coverage – Nov. 8

By Keegan Mager posted 11-09-2024
Targeting the telomeres of non-small cell lung cancer cells to overcome resistance to immune checkpoint inhibitors 1492. Telomere-targeting agent THIO in sequence with cemiplimab demonstrates long-term therapeutic benefits beyond treatment cessation - A phase 2 THIO-101 trial in advanced ICI resistant NSCLC patients. Victor Zaporojan (MAIA Biotechnology, Inc., Chicago, IL, USA) presented an ongoing phase 2 study investigating 6-thio-2’-deoxyguanosine (6-thio-dG; THIO), a first-in-class small molecule targeting telomerase positive (TERT+) cancer cells, in combination with cemiplimab for patients with advanced non-small cell lung cancer ...
0 comments

ESMO Congress 2024 - Sept. 15 and Sept. 16

By Thomas Martin posted 09-16-2024
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ESMO Congress 2024. Below is a recap of highlighted research presented on Sunday, Sept. 15, 2024 and Monday, Sept.16, 2024. 2024 Scientific Highlights Post-hoc analysis of pre-treatment samples from CheckMate 9ER to identify serum glycoproteomic predictive and prognostic biomarkers for advanced renal cell carcinoma 1694MO. Novel serum glycoproteomic biomarkers predict response to Nivolumab plus Cabozantinib (NIVO+CABO) versus Sunitinib (SUN) in advanced RCC (aRCC): analysis from CheckMate ...
0 comments

ESMO Congress 2024 - Sept. 13 and 14

By Thomas Martin posted 09-16-2024
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ESMO Congress 2024. Below is a recap of highlighted research presented from Friday, Sept. 13, 2024 and Saturday, Sept. 14, 2024. 2024 Scientific Highlights Comparing overall survival associated with BCMA-targeting CAR T cell therapies vs. bispecific antibodies for multiple myeloma 802MO. Real-world comparison of overall survival between BCMA - bispecific and CAR-T therapies in multiple myeloma Junmin Song (Albert Einstein College of Medicine, Bronx, NY, United States of America) ...
0 comments

ASCO 2024 Annual Meeting (June 4)

By Thomas Martin posted 06-05-2024
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ASCO 2024 Annual Meeting. Below is a recap of highlighted research presented from Tuesday, June 4, 2024. 2024 Scientific Highlights Safety and efficacy of immune checkpoint inhibitor atezolizumab in patients with advanced solid tumors with high tumor mutation burden LBA2509. Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial. Rafal Dziadziuszko (Department of Oncology & Radiotherapy and Early Phase Clinical Trials Centre, Medical ...
0 comments

ASCO 2024 Annual Meeting (June 3)

By Thomas Martin posted 06-04-2024
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ASCO 2024 Annual Meeting. Below is a recap of highlighted research presented from Monday, June 3, 2024. 2024 Scientific Highlights Combination therapy with lenvatinib and pembrolizumab is associated with clinical benefits for advanced renal cell carcinoma across a variety of biomarker subtypes 4504. Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial. Toni K. Choueiri (Dana Farber Cancer Institute, Boston, MA) reported biomarker analyses ...
0 comments

ASCO 2024 Annual Meeting (June 2)

By Thomas Martin posted 06-03-2024
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ASCO 2024 Annual Meeting. Below is a recap of highlighted research presented from Sunday, June 2, 2024. 2024 Scientific Highlights Blockade of TIGIT improves the anti-tumor efficacy of pembrolizumab for previously treated advanced mismatch repair-deficient endometrial cancer 5502. Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study. Carlos ...
0 comments

ASCO 2024 Annual Meeting (June 1)

By Thomas Martin posted 06-02-2024
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ASCO 2024 Annual Meeting. Below is a recap of highlighted research presented from Saturday, June 1, 2024. 2024 Scientific Highlights Safety and efficacy of a cell-based immunotherapeutic vaccine combined with durvalumab for second-line treatment of HPV 16- or 18-positive cervical cancer 5513. An open label, single arm phase II, multicenter trial of durvalumab and BVAC-C, in patients with HPV 16- or 18-positive cervical cancer and failure of first-line platinum-based chemotherapy (DURBAC). ...
0 comments

ASCO 2024 Annual Meeting (May 31)

By Thomas Martin posted 06-01-2024
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the ASCO 2024 Annual Meeting. Below is a recap of highlighted research presented from Friday, May 31, 2024. 2024 Scientific Highlights Phase I study of immune checkpoint inhibition for advanced secondary angiosarcomas 11513. Cemiplimab in locally advanced and/or metastatic secondary angiosarcomas (CEMangio): A phase II clinical trial. Stefan van Ravensteijn (Radboud UMC, Nijmegen, Gelderland, Netherlands) presented a single-arm multicenter phase II clinical trial investigating the ...
0 comments

AACR Annual Meeting 2024

By Thomas Martin posted 04-11-2024
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the 2024 AACR Annual Meeting. Below is a recap of highlighted research presented from Friday, April 5–Wednesday, April 10, 2024. 2024 Scientific Highlights Long-term follow-up of CD70-targeting allogeneic CAR T cell therapy for refractory clear cell renal cell carcinoma CT002. CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Long-term follow-up and translational data from the phase 1 COBALT-RCC study ...
0 comments

March 15, 2024: Meeting of the Oncologic Drugs Advisory Committee

By Thomas Martin posted 03-19-2024
The Society for Immunotherapy of Cancer (SITC) is pleased to present a summary of the U.S. Food & Drug Administration (FDA) Meeting of the Oncologic Drugs Advisory Committee (ODAC) . Below is a recap of highlighted research presented from Friday, March 15, 2024. Morning session: Supplemental biologics license application (sBLA) 125746.7 for ciltacabtagene autoleucel Ciltacabtagene autoleucel (cilta-cel, CARVYKTI), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell therapy initially obtained approval for adult patients with relapsed or refractory multiple myeloma (r/r MM) after four ...
0 comments

ASH Annual Meeting 2023

By SITC Communications posted 12-13-2023
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the 2023 ASH Annual Meeting. Below is a recap of highlighted research presented from Saturday, Dec. 9–Tuesday, Dec. 12, 2023 2023 Scientific Highlights Real-world safety and efficacy study of the BCMAxCD3 bispecific antibody teclistamab for relapsed or refractory multiple myeloma 91. Real-world safety and efficacy of teclistamab for patients with heavily pretreated relapsed-refractory multiple myeloma Danai Dima (Cleveland Clinic, Cleveland, OH, USA) ...
0 comments

ESMO IO Congress 2023

By SITC Communications posted 12-11-2023
2023 Scientific Highlights The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the 2023 ESMO Iummuno-Oncology Congress. Below is a recap of highlighted research presented from Wednesday, Dec. 6–Friday, Dec. 8, 2023 Results from GDFATHER-1/2, the first in-human trial of visugromab, a GDF-15 neutralizing antibody 118O. Definitive results for NSCLC and bladder cancer cohorts in the phase 2a trial of visugromab (CTL-002) in advanced/metastatic anti-PD/PD-L1 relapsed/refractory solid tumors (GDFATHER-trial) Ignacio ...
0 comments

SITC 2023 SCIENCE COVERAGE (NOV. 5)

By SITC Communications posted 11-05-2023
Use of vaccines to boost CAR T efficacy and promote antigen spreading for long-term anti-tumor activity 286. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity Leyuan Ma (Children’s Hospital of Philadelphia, Philadelphia, PA, USA) reported results from a study of a synthetic vaccine (amph-vax) to enhance CAR T cell activity against solid tumors. Amph-vax consisted of a CAR-ligand linked to albumin-binding poly (ethylene glycol)-phospholipid and formulated with a cyclic-di-GMP (STING agonist). Fluorescently labeled amph-vax targeted lymph nodes and associated with antigen presenting cells ...
0 comments

SITC 2023 SCIENCE COVERAGE (NOV. 4)

By SITC Communications posted 11-04-2023
Correlation of tertiary lymphoid structures with survival benefits in patients treated with first line atezolizumab for metastatic lung cancer 606. IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab Barzin Nabet (Genentech, South San Francisco, CA, USA) presented an analysis to evaluate the clinical utility of tertiary lymphoid structures (TLS) as a biomarker associated with clinical benefits from immunotherapy in patients with untreated metastatic non-small cell lung cancer (mNSCLC). Prior studies have indicated that B-cell and plasma-cell ...
0 comments

SITC 2023 Science Coverage (Nov. 3)

By SITC Communications posted 11-03-2023
Neutrophils are important for the destruction of heterogenous tumors in mouse models of melanoma 878. T cell immunotherapies recruit and activate neutrophils to eliminate tumor antigen escape variants Daniel Hirschhorn (Weill Cornell Medical and Graduate Schools, New York, NY, USA) presented a study investigating the mechanisms of immune-mediated destruction of heterogeneous tumors that contain antigen-loss variants. Selective pressures of the immune system create heterogeneity and antigen-loss variants within tumors, and this heterogeneity often leads to resistance to T cell-targeted immunotherapies. Mouse models of Trp1+ B16 melanoma ...
0 comments

ESMO Congress 2023

By SITC Communications posted 10-25-2023
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the 2023 ESMO Congress. Below is a recap of highlighted research presented from Friday, October 20 through Tuesday, October 24, 2023. Exploring the clinical effectiveness of perioperative immune checkpoint inhibitors in combination with chemotherapy for advanced gastric and gastroesophageal junction cancer LBA74. Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study Kohei Shitara ...
0 comments

ASCO ANNUAL MEETING 2023 (JUNE 6)

By SITC Communications posted 06-06-2023
Lisocabtagene maraleucel for relapsed or refractory chronic lymphocytic leukemia and small lymphocytic leukemia 7501. Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004. Tanya Siddiqi (City of Hope National Medical Center, Duarte, CA) presented efficacy and safety data from the primary efficacy analysis set (n=87) of TRANSCEND CLL 004, which examined lisocabtagene maraleucel (liso-cel), a CD19-directed CAR T cell product in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The Primary ...
0 comments